Clinical Trials Browser

Hematologic Neoplasms × Whole-Body Irradiation × 90 days × Clear all

NCT05436418 2026-03-18

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT01203722 2026-02-19

Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

Phase 1/2 Completed

87 enrolled 24 charts

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Lymphoma, Hematologic Neoplasms

NCT03032783 2026-01-29

A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity

Phase 2 Completed

Other hematologic neoplasm

Hematologic Neoplasms

NCT03159702 2026-01-27

Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation

Phase 2 Completed

43 enrolled 9 charts

Other hematologic neoplasmPlasma cell

Hematologic Diseases, Multiple Myeloma, Hematologic Neoplasms

NCT06252870 2026-01-26

CY-MET-RIC

Phase 2 Recruiting

Other hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms

NCT07162038 2026-01-23

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

Phase 1 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT04959175 2026-01-21

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Phase 1/2 Recruiting

Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT04395222 2026-01-06

Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

Phase 2 Active not recruiting

21 enrolled 15 charts

Other hematologic neoplasm

Hematologic Neoplasms